Ketamine for treatment-resistant obsessive-compulsive disorder: Double-blind active-controlled crossover study
We provide further preliminary evidence for the efficacy and tolerability of IM ketamine in an outpatient cohort of OCD. Additional work is required to establish the optimal dosing regimen and longer-term role of ketamine for OCD. These findings are encouraging given the well-known limitations that exist for treatments in this area.
Authors
- Shona Neehoff
- Neil McNaughton (ORCID: https://orcid.org/0000-0003-4348-8221)
- Paul Glue (ORCID: https://orcid.org/0000-0002-7305-2800)
- Corinne Muirhead (ORCID: https://orcid.org/0000-0002-6269-6459)
- Shabah M. Shadli (ORCID: https://orcid.org/0000-0002-3607-3469)
- Bridget Kimber
- Natalie J. Medlicott (ORCID: https://orcid.org/0000-0001-9778-1947)
- Ben Beaglehole (ORCID: https://orcid.org/0000-0002-9521-1745)
- Aroha de Bie
- Rachel Day-Brown
Institutions
- Charles Sturt University (AU)
- University of Otago (NZ)
Publication Details
- Journal
- Journal of Psychopharmacology
- Published
- 2024-11-28
- DOI
- https://doi.org/10.1177/02698811241301215
- Citations
- 8
- Primary Topic
- Obsessive-Compulsive Spectrum Disorders
- Type
- article
- Field-Weighted Citation Impact
- 5.11
Funders
- Health Research Council of New Zealand